5-hydroxymethylcytosine in Human Cancers

Case ID:
C11663

C11663: 5hmC: A Novel Marker for Cancer Detection

Novelty:

The invention is a novel marker that can be detected in cancers using immunohistochemical (IHC) staining methods.

Value Proposition:

Cancers are often diagnosed in advanced stages, jeopardizing cancer patients’ chance to survive. This technique can detect different types of solid cancers from early to late stage. Other advantages include:

- Highly sensitive
- Easy to perform in formalin fixed paraffin embedded tissues
- The Inventors have developed a robust IHC method for detection of 5hmC marker in cancers

Technical Details:

Johns Hopkins researchers found that highest 5-hydroxymethylcytosine (5hmC) levels were observed in terminally differentiated cells, while less differentiated tissue stem/progenitor cell compartments had very low 5hmC levels. Furthermore, 5hmC levels were profoundly reduced in carcinoma of the prostate, breast and colon compared to normal tissues. These findings suggest a distinct role for 5hmC in tissue differentiation, and provide evidence for its large-scale loss in cancers.

Looking for Partners:

To develop and commercialize the technology as a diagnostic tool for different types of cancers. It may also be a therapeutic target in cancers.

Stage of Development:

Discovery

Data Availability:

Data from human and mouse tissues

Publications/Associated Cases:

Oncotarget. 2011Aug; 2(8):627-37

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
5-hydroxymethylcytosine in Human Cancers ORD: Ordinary Utility United States 13/956,879 9,297,806 8/1/2013 3/29/2016 8/1/2033 Granted
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Michael Woods
mwoods19@jh.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum